Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0001199
UniProt IDP35052
Primary gene name(s)GPC1
Synonym gene name(s)unknown
Protein nameGlypican-1 [Cleaved into: Secreted glypican-1]
Protein functionCell surface proteoglycan that bears heparan sulfate. Binds, via the heparan sulfate side chains, alpha-4, V collagen and participates in Schwann cell myelination, By similarity. May act as a catalyst in increasing the rate of conversion of prion protein PRPN(C to PRNP(Sc via associating, via the heparan sulfate side chains with both forms of PRPN, targeting them to lipid rafts and facilitating their interaction. Required for proper skeletal muscle differentiation by sequestering FGF2 in lipid rafts preventing its binding to receptors, FGFRs and inhibiting the FGF-mediated signaling. {ECO:0000250, ECO:0000269|PubMed:19936054, ECO:0000269|PubMed:21642435}.
Subcellular locationCell membrane;
Lipid-anchor, GPI-anchor;
Extracellular side. Endosome. Note=S-nitrosylated form recycled in endosomes. Localizes to CAV1-containing vesicles close to the cell surface. Cleavage of heparan sulfate side chains takes place mainly in late endosomes. Associates with both forms of PRNP in lipid rafts. Colocalizes with APP in perinuclear compartments and with CP in intracellular compartments. Associates with fibrillar APP Abeta peptides in lipid rafts in Alzheimer disease brains.;
SUBCELLULAR LOCATION: Secreted glypican-1: Secreted, extracellular space.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P35052
Gene Ontology
(Biological Process)
Complete annatation
axon guidance [GO:0007411];
glycosaminoglycan biosynthetic process [GO:0006024];
glycosaminoglycan catabolic process [GO:0006027];
glycosaminoglycan metabolic process [GO:0030203];
heparan sulfate proteoglycan catabolic process [GO:0030200];
myelin assembly [GO:0032288];
negative regulation of fibroblast growth factor receptor signaling pathway [GO:0040037];
positive regulation of skeletal muscle cell differentiation [GO:2001016];
retinoid metabolic process [GO:0001523];
Schwann cell differentiation [GO:0014037]
Gene Ontology
(Molecular Function)
Complete annatation
copper ion binding [GO:0005507];
fibroblast growth factor binding [GO:0017134];
laminin binding [GO:0043236]
Gene Ontology
(Cellular Component)
Complete annatation
anchored component of membrane [GO:0031225];
endosome [GO:0005768];
extracellular exosome [GO:0070062];
extracellular space [GO:0005615];
Golgi lumen [GO:0005796];
integral component of plasma membrane [GO:0005887];
lysosomal lumen [GO:0043202];
membrane raft [GO:0045121];
plasma membrane [GO:0005886];
proteinaceous extracellular matrix [GO:0005578]
Protein-protein interaction109079
Phylogenetic treeP35052
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-0.4061320908600460.3661262468100510.487798008310824
AZA vs. DISU-0.2737682465316470.5122105435280830.938109377229618
AZA vs. IL7-0.4291060617550680.2769969892196630.999311006273513
AZA vs. SAHA0.3600101986910810.3558798222217820.724709117054083
DISU vs. CD30.1207785640608170.7851355882162530.852429692939485
DISU vs. IL7-0.1660983794793930.6634162654457520.905205194634448
DISU vs. SAHA0.6371765879660370.09068476031643290.384447263777485
DMSO vs. AZA-0.06725070403897860.8522770375789091
DMSO vs. CD30.3299884709389650.3963297246564670.510928230527954
DMSO vs. DISU0.2048710658663280.5585250635829330.924836638387915
DMSO vs. IL7-0.3540681673590710.2669752250715730.767539423873874
DMSO vs. SAHA0.4228865162857520.1742485754882050.505310196645122
HIV vs. Mock in Activation0.6750631716924970.2997165364318610.999983755607037
HIV vs. Mock in Latency0.2075213653979620.6271835117740740.999834320637052
IL7 vs. CD3-0.02070419363097440.9597241104503520.975976353853607
SAHA vs. CD30.744293786230860.06456690807624780.122467571789959
SAHA vs. IL70.7885144261547070.02551368502380260.117856863738566
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.0870004 0.726983
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

not found

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
4ACR X-ray 2.5Å A/B/C/D=24-479.
4AD7 X-ray 2.9Å A/B/C/D=24-529.
4BWE X-ray 2.4Å A/B/C/D=24-479.
4YWT X-ray 2.3Å A/B/C/D=24-527.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
capsid interacts with 25505242

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa05205 Proteoglycans in cancer - Homo sapiens (human)